8-K: Collegium Pharmaceutical Reports Q1 2026 Results, Eyes AZSTARYS Acquisition

Collegium Pharmaceutical announced strong first quarter 2026 financial results, with net revenues up 9% year-over-year, driven by significant growth in JORNAY PM and its pain portfolio, while advancing its planned acquisition of AZSTARYS.

Summary

• Collegium Pharmaceutical reported first quarter 2026 net revenues of $193.5 million, a 9% increase compared to the same period last year.
• JORNAY PM, a treatment for ADHD, saw its net revenue increase by 36% year-over-year to $38.9 million, with prescriptions up 14%.
• The company's pain portfolio generated $154.6 million in net revenue, a 4% increase year-over-year.
• Collegium is on track to close the acquisition of AZSTARYS in the second quarter of 2026 for $650 million in cash, with potential for additional milestone payments.
• The company ended the quarter with $421.8 million in cash, cash equivalents, and marketable securities.
• Full-year 2026 guidance for the current business has been reaffirmed, excluding the impact of the AZSTARYS acquisition.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth in key products and progress on a significant strategic acquisition, although operating expenses are also increasing.

Positives

• Net revenues increased by 9% year-over-year to $193.5 million.
• JORNAY PM net revenue grew 36% year-over-year to $38.9 million, with prescriptions up 14% and prescribers up 17%.
• Pain portfolio net revenues increased 4% year-over-year to $154.6 million.
• Belbuca net revenue increased 2% year-over-year to $52.6 million.
• Xtampza ER net revenue increased 7% year-over-year to $50.8 million.
• Adjusted EBITDA increased 9% year-over-year to $103.9 million.
• GAAP net income increased significantly to $14.5 million from $2.4 million in the prior year.
• Cash, cash equivalents, and marketable securities stood at $421.8 million at the end of the quarter.

Negatives

• GAAP operating expenses increased by 14% year-over-year to $86.4 million.
• Adjusted operating expenses increased by 11% year-over-year to $69.3 million.
• Nucynta Franchise net revenue was flat year-over-year at $47.0 million.

Risks

• Risks associated with the completion of the AZSTARYS acquisition, including potential delays or failure to receive regulatory approvals.
• The possibility that the anticipated benefits of the AZSTARYS acquisition may not be realized or may not be realized within the expected timeframe.
• Uncertainty regarding the future financial performance of products.
• Ability to commercialize and grow sales of products.
• Potential for patent infringement or other litigation.
• Risks related to obtaining and maintaining regulatory approval and potential label restrictions.
• Market acceptance and competition from other products.
• Regulatory developments in the U.S. and compliance with stringent government regulations.

Future Outlook

The company reaffirms its full-year 2026 guidance for Product Revenues, Net, JORNAY PM Revenue, Net, and Adjusted EBITDA for its current business, excluding the impact of the planned AZSTARYS acquisition. Guidance is expected to be updated following the close of the acquisition.

Management Comments

• "In the first quarter, we made meaningful progress on our 2026 strategic priorities, including delivering strong performance for JORNAY PM and continued durability from our pain portfolio."
• "We generated additional growth for JORNAY PM, with net revenue up 36% and prescriptions rising 14% driven by gains in both new prescribers and market share."
• "The pending acquisition of AZSTARYS represents an important next step in strengthening our ADHD portfolio, extending revenues into the late 2030s, and expanding our growth profile."
• "We delivered strong first quarter results, marked by significant net revenue growth for JORNAY PM, robust contributions from our pain portfolio, and impressive operating cash flows."
• "We expect the acquisition [of AZSTARYS] to be immediately accretive upon close and to extend our revenues into the late 2030s."

Industry Context

StockSavvy.ai notes that Collegium Pharmaceutical's Q1 2026 results reflect continued growth in its ADHD segment with JORNAY PM, alongside stable performance in its pain management portfolio. The strategic acquisition of AZSTARYS signals a clear intent to bolster its position in the ADHD market, aiming for extended revenue streams and enhanced growth, a common strategy among biopharmaceutical companies seeking to diversify and strengthen their product pipelines.

Comparison to Industry Standards

• The 9% year-over-year revenue growth for Collegium's overall business is moderate compared to the high-growth rates often seen in early-stage biotechs, but aligns with mature product portfolios and strategic acquisitions in the pharmaceutical sector.
• JORNAY PM's 36% revenue growth and 14% prescription growth outpace the average growth for established ADHD treatments, indicating strong market penetration and competitive positioning.
• The pain portfolio's 4% growth is consistent with the market dynamics for established pain medications, where differentiation and market share defense are key.
• The planned acquisition of AZSTARYS for $650 million, with potential milestones, is a significant strategic move, comparable to other mid-to-large-sized pharmaceutical companies acquiring complementary assets to expand their therapeutic areas and revenue bases.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact expected from continued revenue growth, strategic acquisition of AZSTARYS, and reaffirmed financial guidance, potentially leading to increased shareholder value.
• Employees: Potential for growth and integration challenges related to the AZSTARYS acquisition; continued focus on compensation strategies including stock-based compensation.
• Customers/Patients: Continued access to JORNAY PM and pain portfolio products; potential for new treatment options with AZSTARYS, pending acquisition completion.
• Creditors: The company is utilizing a $300 million delayed draw term loan for the AZSTARYS acquisition, impacting its debt structure.

Next Steps

• Close the acquisition of AZSTARYS in the second quarter of 2026.
• Integrate AZSTARYS into Collegium's existing ADHD portfolio.
• Update 2026 financial guidance following the close of the AZSTARYS acquisition.
• Participate in the Jefferies Global Healthcare Conference on June 3, 2026.
• Hold the 2026 Annual Meeting of Shareholders on May 14, 2026.

Key Dates

Recommendation

The company is demonstrating solid execution with growth in key products and a strategic acquisition that promises future expansion. However, the integration risks of AZSTARYS and the increasing operating expenses warrant a cautious 'hold' stance until the acquisition's benefits are more clearly realized and integrated.

Keywords

Collegium Pharmaceutical, 8-K Filing, Q1 2026 Results, JORNAY PM, ADHD Treatment, Pain Management, AZSTARYS Acquisition, Financial Results